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Abstract
Purpose: The objective of the present study was to correlate the prostate-specific antigen (PSA) level and Gleason score with the
baseline bone scan results in patients with newly diagnosed prostate cancer and try to determine a group of patients whose risk of
bone metastases is low enough to omit safely this staging modality. Methods: This retrospective study included 84 consecutive
patients with newly diagnosed prostate cancer (Pca) who underwent a staging bone scan in Nuclear Medicine department be-
tween August 2013 and August 2014. Data were collected on age, bony pain, prostate-specific antigen (PSA) level and Gleason
score, then, bone scan results were analyzed with respect to these parameters. Bone scan was recorded as positive, negative or
equivocal. In case of equivocal lesions, a single-photon emission computed tomography combined with computed tomography
(SPECT-CT) was performed allowing a better morphological precision. Results: The median age of the patients was 71, 38 years.
Bone metastases were detected in 41 patients (49% of cases), bony pain was a reliable presenting sign of skeletal involvement.
Both prostate-specific antigen (PSA) level and Gleason score were independent predictors of positive bone scan. However, the
combination of these two parameters enhanced predictability of bone scan results. According to this study, the risk to develop a
bone metastasis was very low in asymptomatic patients with PSA level < 20 ng/ml irrespective of the Gleason score or with PSA
level < 30 ng/ml associated to a Gleason score < 7. Conclusion: The present study discourages the routine use of bone scan as a
pre-treatment staging modality in asymptomatic patients with PSA level < 20 ng/ml irrespective of the Gleason score or with PSA
level < 30 ng/ml associated to a Gleason score < 7, allowing considerable cost savings and decreasing time from diagnosis to
treatment.
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Introduction
Prostate cancer is considered currently the most common
malignancy and the second leading cause of cancer death
among men aged over 50 years in developed countries. Alt-
hough it is one of the few cancers that grow so slowly that it
may never be life threatening, it can show an aggressive pat-
tern that may spread and cause the death of patients mainly
due to malignant involvement of bone.1, 2 Therefore, early
diagnosis of metastatic bone involvement in prostate cancer is
crucial for selecting appropriate therapy, to assess the pa-
tient’s prognosis, and to evaluate the efficacy of bone-specific
treatments that may reduce future bone associated morbidi-
ty.1
Historically, nuclear bone scan is the investigation of choice
to evaluate bone metastases. It has a great sensitivity; how-
ever, it lacks specificity prompting the need for further im-
aging that, in turn, create anxiety for patients, add consider-
able cost, and delay therapy.3
The advent and the development of different techniques
for measurement of prostate specific antigen (PSA) level since
the 1990s has led to spectacular changes in the incidence, age
and cancer stage at diagnosis. Following its introduction, the
test soon became the most commonly used screening method
for the diagnosis and follow-up in the management of pros-
tate cancer patients.1, 3 More recent studies demonstrated
Gleason grade to be an independent predictor for positive
bone scan and that its utilization may avoid a considerable
number of bone scans.4
International guidelines uniformly suggest no routine staging
for bone metastases in low-risk prostate cancer allowing more
selectivity in performing bone scans.5 The European Associa-
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tion of Urology (EAU) guidelines, updated in April 2014, state
that bone scan is recommended in asymptomatic patients
only if the PSA level > 10 ng/mL or Gleason score ≥ 8 or
clinical stage ≥ T3 (intermediate-/high-risk situations). It
should also be obtained in symptomatic patients, inde-
pendently of the PSA level, Gleason score or clinical stage.6
This study was conducted to correlate bone scan results with
prostate-specific antigen level and Gleason score in patients
with newly diagnosed prostate cancer with the main aim of
identifying a group of patients with a low probability of bone
metastases who did not require a pretreatment nuclear bone
scan, and assessing the safety of implementing the EAU
guidelines in our patients.
Methods and Materials
Patients
This is a retrospective and analytic study reviewing 84 con-
secutive patients with newly diagnosed prostate cancer re-
ferred to Nuclear Medicine department to undergo a staging
bone scan between August 2013 and August 2014. All pa-
tients with known Gleason Score and with PSA level meas-
ured in absence of treatment were included. Data were
gathered on age, bony pain, PSA level, Gleason score and
associated bone scan findings.
Bone scan
Bone scintigraphy was carried out 2-4 h after an intravenous
injection of 740 MBq of 99mTc-methylene diphosphonate.
Planar images were acquired on a hybrid SPECT-CT dual
head Gamma camera (SYMBIA T6, Siemens Medical Solu-
tions). Anterior and posterior whole body planar images were
acquired in a continuous mode at a speed of 15 cm/min; using
parallel-hole, low-energy, high resolution collimators, with
the patient in the supine position. Immediately after acquisi-
tion, the planar images were evaluated by a nuclear medicine
consultant to decide the need for an additional imaging in the
form of SPECT or SPECT-CT.
SPECT was done only for the volume defined based on planar
bone scan. The acquisition orbits were body contour orbits
over 360° arcs, with the use of 64 stops. For 64 stops, emission
data were acquired for 30 s per stop. The image acquisition
matrix was 128×128. SPECT was followed by CT examination
with acquisition parameters of 130 kV, 100 mAs, using
standard filters and slice thickness of 2 mm.
Results
The median age of our patients was 71, 38 years (50 – 92
years). The most affected age group was between 70 and 80
years (49% of all patients) Figure 1.
FIG. 1: Distribution of patients according to their age group.
All patients included in our study had a prostate adenocar-
cinoma, the other histological types including urothelial
carcinoma, sarcoma or lymphoma have not been found.
FIG. 2: Contribution of the SPECT_CT in differentiating between a benign and a malignant condition.
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Bone scan findings were tentatively classified into three cat-
egories, positive in 35 patients, negative in 26 patients and
equivocal in 23 patients. SPECT CT was performed in patients
who had indeterminate lesions on planar bone scintigraphy;
74% of these lesions were rated as benign and 26% as malig-
nant, predominantly sclerotic in 83% of cases and lytic in
17% of cases in computed tomography images (Figure 2).
Accordingly, the overall proportion of positive bone scans
was 49% (41/84).
FIG. 3: Predilection sites of bone metastases.
The predilection sites of bone metastases were:
 Pelvis, the most commonly involved (88%),
 Spine (83%),
 Ribcage (83%),
 Upper limbs (56%),
 Lower limbs (51%),
 Skull, the less involved (44%) (Figure 3).
Bone metastases were multiple in 88% of cases against only
12% of solitary lesions.
FIG. 4: Skeletal symptoms in positive and negative bone scans (BS).
The presence of skeletal symptoms was definitely a reliable
presenting sign of bone involvement (Figure 4). Table 1
shows the average PSA level, median Gleason score and me-
dian age results in metastatic and non-metastatic patients,
revealing that the first two parameters were significantly
higher in metastatic patients. However, there weren’t t any
significant difference in age between the two categories.
TABLE 1: Median PSA level, Gleason score and median age in pa-
tients with positive and negative bone scans.
Positive; n=41 Negative; n=43
Median PSA level (ng/ml) 257.6 78.15
Median Gleason score 7.8 7.02
Median age (years) 70.7 71.9
n= number of patients
FIG. 5: Bone scan results in each PSA bracket.
FIG. 6: Bone scan results in each Gleason bracket.






<10 4 7 11
10-19, 9 3 13 16
20-29, 9 2 4 6
30-49, 9 2 5 7
>50 30 14 44
Total 41 43 84
PSA= Prostate specific antigen






<7 4 14 18
7 15 12 27
>7 22 17 39
Total 41 43 84
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TABLE 4: Number of positive bone scans with respect to PSA level
and the Gleason score in asymptomatic patients.
Gleason Score
<7 7 >7
PSA(ng/ml) n BM+ n BM+ n BM+
<10 2 0 2 0 3 0
10-19, 9 5 0 3 0 3 0
20-29, 9 2 0 0 0 2 1
30-49, 9 2 1 3 0 2 1
≥50 3 1 7 5 12 5
BM +, positive bone metastases
According to Figure 5 and 6, Table 2 and 3, showing the
relationship between PSA level, Gleason score and bone scan
results, we concluded that the risk of occurrence of bone
metastases increased with the elevation of PSA level or with
Gleason score ≥7. Hence, these two parameters are considered
independent predictors of bone scan positivity.
Combining PSA level and Gleason score results in asympto-
matic patients (51 patients) as shown in Table 4, we obtained
the following results:
 None of the patients with no bony pain and
with PSA level <20ng/ml had a positive bone
scan irrespective of the Gleason score.
 None of the patients with no bony pain, with
PSA level < 30ng/ml and with a Gleason score <
7 had a positive bone scan.
Discussion
The pretreatment staging of prostate cancer directs thera-
peutic decision and provides important prognostic infor-
mation. Skeleton is a common site of metastases, thus, early
detection of bone and bone marrow metastases is essential for
proper patient management.2
However, the detection of skeletal involvement in newly
diagnosed prostate cancer is influenced by three major
prognostic factors; PSA, clinical stage and Gleason Grade.7
The significant relationship between these parameters and
the likelihood of positive bone scan has led to reduce a high
number of potentially avoidable staging bone scan studies
with a significant reduction of superfluous costs for the health
care system.8
According to the European Association of Urology (EAU)
guidelines, updated in April 2014, bone scan is recommended
in asymptomatic patients only if the PSA level > 10 ng/mL or
Gleason score ≥ 8 or clinical stage ≥ T3 (intermedi-
ate-/high-risk situations). It should also be obtained in
symptomatic patients, independently of the PSA level,
Gleason score or clinical stage.6
Chybowski et al. 9 had an experience with 521 patients with
untreated newly diagnosed prostate cancer. They demon-
strated that bone metastases did not occur in patients with
PSA levels < 10 ng/ml, but it did occur in 1 patient (1%) with
a PSA level of 10–19,9 ng/ml.
In another study performed by Gleave et al.10, scans were
positive in none of the 290 patients with PSA levels below 10
ng/ml, 4 of 88 (4.5%) with PSA levels between 10 and
19,9ng/ml.
Mcarthur et al. 4, found in his large study including 672 pa-
tients that PSA level <20 ng/ml, combined with a Gleason
score < 8, had a negative predictive value for bone metastases
of 100%.
For Ritenour et al. 3, bone scans can be omitted in asympto-
matic patients with PSA<10 ng/ml irrespective of the Gleason
grade or in patients with Gleason score ≤7 with PSA ≤30
ng/ml.
In Asiatic population, several studies conducted by Miranda
et al. 11, Megumi et al. 12, and Kosuda et al. 13, concluded that
bone scan might be avoidable in asymptomatic patients with
PSA level ≤ 10 ng/ml. A positive relation between the PSA
level, Gleason score and presence of bone metastases on bone
scan was demonstrated in our study, having a trend in line
with the other studies.
Comparing the overall proportion of positive bone scans in
this study to other previous studies, we found a substantial
difference with higher rates of bone metastases: 49% vs. 4%
in Ritenour et al. study 3, 8% in Mcarthur et al. study 4, 30% in
Wymenga et al. study 14, 39, 7% in Al-ghazo et al. study 15.
This high rate of positive bone scans is partly due to the PSA
screening programs weakly carried out in our country;
therefore patients consult in a late stage of prostate cancer.
Conclusion
In the present study, we concluded that the PSA level and the
Gleason score can be used to predict accurately the occur-
rence of bone involvement in patients with newly diagnosed
prostate cancer. Moreover, we defined a group of patients in
whom a baseline bone scan could be safely omitted: asymp-
tomatic patients with PSA < 20 ng/ml irrespective of the
Gleason grade, or patients with PSA level < 30 ng/ml and with
a Gleason score < 7.
By implementing the results of this study, bone scans could
have been avoided in 30/84 patients allowing considerable
cost savings and decreasing times from diagnosis to treatment.
However, there are some limitations, mostly due to the low
number of patients, the retrospective aspect of the study that
may be prone to a possible selection bias. In addition, some
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other important criteria were not considered like clinical
tumor stage and the tumor differentiation degree.
Therefore, the outcome of the study needs to be confirmed by
a prospective cohort reviewing patients referred to Nuclear
Medicine department for the pre-treatment staging of their
newly diagnosed prostate cancer.
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